IL-24 exhibits its anti-tumor activity in a broad spectrum of cancers including melanoma [129,130,131] through inhibition of PI3K, EGFR, and PKR induction in breast and NSCLC [132,133]. This evidence concerns the gene EGFR and neoplasm.